Table 2.
Changes in PSMA uptake after ADT
| Lesion type | Lesions (n) at baseline PSMA PET | Increase (≥ 20%) of PSMA uptake, n (%) | ∆SUVmax%, median (IQR; range) | No change/decrease (< 20%) of PSMA uptake, n (%) | ∆SUVmax% median (IQR; range) |
|---|---|---|---|---|---|
| Prostate | 57 | 6 (11%) |
+ 45% (20–106; 23–134) |
49 (89%) |
− 28% (− 45 to − 7; − 78 to 14) |
| Lymph nodes | 314 | 33 (11%) |
+ 60% (32–114; 20–222) |
281 (89%) |
− 51% (− 74 to − 21; − 99 to 9) |
| Bone | 406 | 104 (26%) |
+ 50% (32–72; 20–161) |
302 (74%) |
− 33% (− 53 to − 15; − 90 to 14) |
| Visceral (lung) | 5 | - | - | 5 (100%) |
− 40% (− 49 to − 22; − 53 to − 16) |